Blog
RSS FeedPosted by Michael Wonder on 05 Jul 2024
CSL Behring announces first two patients treated with Hemgenix (etranacogene dezaparvovec) gene therapy for haemophilia B in Europe
4 July 2024 - CSL Behring today announced that two haemophilia B patients were treated with the gene therapy Hemgenix ...
Posted by Michael Wonder on 04 Jul 2024
RSV vaccination: protecting older people from serious complications
4 July 2024 - Referred by the Ministry of Health, the High Authority for Health has assessed the opportunity to integrate ...
Posted by Michael Wonder on 03 Jul 2024
HAS clarifies the framework of the “bet” on early access to medicines
24 June 2024 - Committed to a process of continuous development of its methods, the High Authority of Health is launching ...
Posted by Michael Wonder on 04 Mar 2024
Together for high standards in the assessment of health technologies in Europe from 2025
1 March 2024 - A few months before the EU HTA regulation came into force, a delegation from the French HTA ...
Posted by Michael Wonder on 15 Dec 2023
CSL Behring’s Hemgenix granted first ever direct access in France for haemophilia B gene therapy
13 December 2023 - CSL Behring has been granted Direct Access for Hemgenix (etranacogene dezaparvovec) by the French Ministry of ...
Posted by Michael Wonder on 06 Oct 2023
Amylyx Pharmaceuticals provides update on Accès Compassionnel for AMX0035 in France
5 October 2023 - L’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), the national authority for ...
Posted by Michael Wonder on 17 Aug 2023
Do France, Germany, and Italy agree on the added therapeutic value of medicines?
17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...
Posted by Michael Wonder on 10 Aug 2023
Patient and citizen participation at the organisational level in health technology assessment: an exploratory study in five jurisdictions
8 August 2023 - While patient participation in individual health technology assessments has been frequently described in the literature, patient and ...
Posted by Michael Wonder on 08 Feb 2023
Santhera concludes agreement with French authorities on Raxone reimbursement and plans to submit a request for an early access program for vamorolone
8 February 2023 - Santhera Pharmaceuticals announces that it has secured a final reimbursement agreement with the French authorities related to ...
Posted by Michael Wonder on 24 Jan 2023
HAS updates its recommendations for the proper use of osteoporosis drugs
24 January 2023 - Osteoporosis is a disease whose first cause is ageing and which is characterised by the reduction ...
Posted by Michael Wonder on 01 Dec 2022
Reimbursed access to Bylvay (odevixibat) approved in France for patients with PFIC 1 & 2
30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...
Posted by Michael Wonder on 06 Sep 2022
COVID-19: a global opinion on bivalent vaccines in mid-September
5 September 2022 - The EMA has just modified the marketing authorisations granted to messenger RNA vaccines developed by Moderna and ...
Posted by Michael Wonder on 10 Jul 2022
Monkeypox: a preventive vaccination offered to those most at risk of exposure
8 July 2022 - Faced with the spread of the Monkeypox virus, the kinetics of the epidemic and the difficulties of ...
Posted by Michael Wonder on 02 May 2022
HAS clarifies the framework for use of Xevudy
29 April 2022 - After authorising early access to Xevudy (sotrovimab) as a curative treatment for COVID-19 on 6 January, HAS ...
Posted by Michael Wonder on 26 Apr 2022
HAS decides in favour of reimbursement of Paxlovid
25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...